Marty, please weigh in on dachmeister's wondering. Or possibly just provide any significance at all of Sangamo's so called notable "Patent Estate". Personally I don't have an ounce of belief there is any significance with the paragraph below. And as it regards to ZF tech, I think the market and big pharma are speaking loud and clear.
Sangamo has prioritized intellectual property as an essential component of their business. They have a dominant proprietary patent estate for zinc fingers design and methods. They also own more CRISPR patents than CRISRP (CRSP), Editas (EDIT) and Intellia (NTLA) combined. The 2019 CRISPR 10k states they own approximately 25 granted patents worldwide, relying primarily on in-licensing which is clouded by ongoing patent litigation."